CD25mAb及联合供体脾细胞诱导心脏移植免疫低反应性

目的观察静脉应用CD25mAb及联合应用供体脾细胞对移植心脏生存时间的影响。方法建立大鼠异位心脏移植模型，术中应用CD25mAb及联合应用供体脾细胞。术后通过腹壁触诊判断移植心脏存活情况。结果CD25mAb组移植心脏生存时间为12．10±4．04天，与未用药组（8．5±2．42天）相比差异有显著性意义（P〈0．05）。CD25mAb＋供体脾细胞组移植心脏生存时间为12．80±3．61天，与单独应用CD25mAb组相比没有明显差异（P〉0．05），但比单独用脾细胞组（8.40±3．50天，P〈0．05）和未用药组有明显延长（P〈0．05）。结论静脉应用CD25mAb及联合应用供体脾细胞均可以延长移植心脏生存时间。

The Induction of Hyporesponse to Heart Allografts by Vein Injecting of CD25mAb or Associated with Donor Splenocytes

Objective To observe the heart aUografts survival time after administration of immunosuppressive agents CD25mAb or associated with donor splenocytes in a single dose on the time of operation. Methods A simplified heterotopic rat heart transplantation model was established and the CD25mAb （1mg/kg） were injected through vein or associated with donor splenocytes （1× 10^9 cells/100g）. The grafts survival was observed by palpating over the abdominal wall postoperation. Results In using CD25mAb group, the average of the survival of heart allograft was 12.10 ± 4.04 days, which had a significant difference compared with those of the no therapy group （8.5 ± 2.42 days, P〈0.05）. In using CD25mAb＋donor splenocytes group, the average survival of heart allografts is 12.80 ±3.61 days, which had no significant difference with those of using CD25mAb alone （P〉0.05）, and much longer than those of using donor splenocytes group （8.40 ±3.50 days, P〈0.05） and no therapy group （P〈0.05）. Conclusion The findings demonstrate that a single injection of CD25mAb or associated with donor splenocytes can induce stable longterm acceptance of heart allografts.